https://glp1decode.com/tags/obesity-treatment/Recent content in Obesity Treatment on GLP-1 Guide — Ozempic, Wegovy, Mounjarohttps://glp1decode.com/images/default-og.pnghttps://glp1decode.com/images/default-og.pngHugoenSat, 04 Jul 2026 00:00:00 +0000https://glp1decode.com/posts/zepbound-tirzepatide-weight-loss-2026/Sat, 04 Jul 2026 00:00:00 +0000https://glp1decode.com/posts/zepbound-tirzepatide-weight-loss-2026/Zepbound (tirzepatide) is the newest GLP-1/GIP dual agonist approved for weight loss. We break down the SURMOUNT trial results, real-world outcomes, side effects, and how it compares to Wegovy and Mounjaro.https://glp1decode.com/posts/mounjaro-vs-wegovy-weight-loss-comparison-2026/Thu, 02 Jul 2026 12:00:00 +0800https://glp1decode.com/posts/mounjaro-vs-wegovy-weight-loss-comparison-2026/Mounjaro (tirzepatide) vs Wegovy (semaglutide) — which is better for weight loss? We compare clinical trial data, real-world results, side effects, mechanism differences, and cost in 2026.https://glp1decode.com/posts/wegovy-vs-ozempic-comparison-2026/Fri, 19 Jun 2026 12:00:00 +0800https://glp1decode.com/posts/wegovy-vs-ozempic-comparison-2026/Wegovy and Ozempic contain the exact same drug (semaglutide), yet they're labeled for different conditions. Here's what actually separates them — dosing, insurance coverage, and real-world results.